Spire Healthcare Group (LON:SPI) Trading Down 21.4% After Analyst Downgrade

Spire Healthcare Group plc (LON:SPI) dropped 21.4% during mid-day trading on Thursday after Deutsche Bank Aktiengesellschaft lowered their price target on the stock from GBX 320 to GBX 300. Deutsche Bank Aktiengesellschaft currently has a buy rating on the stock. Spire Healthcare Group traded as low as GBX 169 ($2.18) and last traded at GBX 176.40 ($2.28). Approximately 3,426,506 shares changed hands during trading, an increase of 447% from the average daily volume of 626,257 shares. The stock had previously closed at GBX 224.50 ($2.90).

Spire Healthcare Group Price Performance

The company has a current ratio of 0.70, a quick ratio of 0.74 and a debt-to-equity ratio of 62.25. The company has a market capitalization of £711.58 million, a PE ratio of 25.22, a P/E/G ratio of 1.06 and a beta of 0.96. The stock has a fifty day simple moving average of GBX 227.28 and a 200-day simple moving average of GBX 229.74.

Spire Healthcare Group (LON:SPI) last posted its earnings results on Thursday, March 6th. The company reported GBX 8.80 ($0.11) earnings per share for the quarter. Spire Healthcare Group had a return on equity of 3.82% and a net margin of 1.96%. Equities analysts anticipate that Spire Healthcare Group plc will post 15.6634747 earnings per share for the current year.

About Spire Healthcare Group

Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics. It offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, bowel treatments, breast screening and surgery, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments.